PIK-PD-1

PIK-PD-1 is an investigational therapy consisting of pluripotent killer T cells engineered to express an anti-programmed cell death protein 1 (PD-1) antibody. The approach aims to enhance the immune system's ability to target and destroy cancer cells by blocking the PD-1 pathway, a key immune checkpoint that tumors exploit to evade immune surveillance. By expressing an anti-PD-1 antibody, these modified T cells are designed both to directly attack tumor cells and disrupt inhibitory signals in the tumor microenvironment, potentially improving antitumor immunity. This strategy represents a novel form of immunotherapy combining cellular therapy with checkpoint inhibition[1].

Other names

anti-programmed cell death protein 1 antibody expressing pluripotent killer T cells